Amphastar Pharmaceuticals, Inc.
AMPH US
AMPH USAmphastar Pharmaceuticals, Inc.
United States Composite- Business
- Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Company News
New Strong Sell Stocks for April 26th
Amphastar Pharmaceuticals Poised for Growth: Strong Generic Pipeline and Strategic Marketing Drive Buy Rating
Amphastar Pharmaceuticals (NASDAQ:AMPH) shareholders YoY returns are lagging the company's 66% three-year earnings growth
Needham Sticks to Its Hold Rating for Amphastar Pharmaceuticals (AMPH)
Amphastar Pharmaceuticals (NASDAQ:AMPH) Offers Savvy Value Investors a Window of Opportunity
Amphastar Pharmaceuticals (AMPH) Stock Moves -1%: What You Should Know
Amphastar Pharmaceuticals (AMPH) Stock Moves -1%: What You Should Know
Amphastar Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
Is Amphastar (AMPH) a Buy as Wall Street Analysts Look Optimistic?
Is Amphastar (AMPH) a Buy as Wall Street Analysts Look Optimistic?
Amphastar Pharmaceuticals (AMPH) Registers a Bigger Fall Than the Market: Important Facts to Note
Amphastar Pharmaceuticals (AMPH) Registers a Bigger Fall Than the Market: Important Facts to Note
Amphastar Pharmaceuticals (AMPH) Stock Sinks As Market Gains: What You Should Know
Amphastar Pharmaceuticals (AMPH) Stock Sinks As Market Gains: What You Should Know
New Strong Sell Stocks for March 18th
Brokers Suggest Investing in Amphastar (AMPH): Read This Before Placing a Bet
Brokers Suggest Investing in Amphastar (AMPH): Read This Before Placing a Bet
Amphastar Pharmaceuticals Inc CFO, EVP & Treasurer William Peters Sells 18,136 Shares
Amphastar Pharmaceuticals Inc Director Michael Zasloff Sells 12,500 Shares
Amphastar Pharmaceuticals to Present at the Barclays 26th Annual Global Healthcare Conference